GESSEL advises Urteste S.A. on a public placement of new issue shares and on transfer of its shares from the NewConnect alternative trading system to the main floor of the Warsaw Stock Exchange. The prospectus was approved by the Polish Financial Supervision Authority on 16 March 2023, with Dom Maklerski Banku Ochrony Środowiska S.A. serving as the issue coordinator.
Our lawyers drew up a comprehensive set of corporate and issue documentation, conducted due diligence of the issuer company, represented it in proceedings for approval of the prospectus and, generally, provided Urteste and Dom Maklerski BOŚ with legal support in all aspects of the project.
This is the second public placement in which we had the pleasure of advising Urteste; we already worked with the company in 2021, when it first floated its shares on the NewConnect market.
Urteste S.A. is a Gdansk-based biotech which is perfecting methods for detecting early-stage cancers on the basis of urine samples. At present, the company has viable test prototypes for ten of the fifteen defined diagnostic objectives.
We take this opportunity to thank Urteste S.A., Dom Maklerski BOŚ, Marcin Hauffa B-Think, and Kamil Majcher for a fruitful cooperation!
Lawyers involved in the project
They may interest you
We advised ANWIM S.A.
On 15 February 2024, the President of the Office of Competition and Consumer Protection (OCCP) approved the acquisition by our long-standing client ANWIM S.A. - part of ...
We advised the partners and founders of PROFIT4YOU Group
We advised the partners and founders of PROFIT4YOU Group in the transaction to sell the company to the TEP Capital fund. On the part of GESSEL, the project was managed ...